🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to scientists.

A Worldwide Challenge

Gonorrhoea infections are on the rise globally, with figures suggesting more than 82 million instances each year. Especially elevated rates are observed in the African continent and nations within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an significant and necessary step in the face of growing infection rates, escalating drug resistance and the very limited available drugs presently on offer.”

Public health authorities are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Authorization

One new antibiotic, alternatively called a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Scientists believe that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This drug, which is additionally indicated for UTIs, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the treatment of multidrug-resistant gonorrhoea, which previously has been outpacing medical innovation.”

Research Study Data and Global Access

According to results detailed in a major medical journal, the new drug cured the vast majority of genital gonorrhoea infections. This establishes an comparable level with the current standard treatment, which uses two antibiotics. The study included over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the authority to make available and distribute the drug in many low-income and middle-income countries.

Doctors directly involved have voiced hope. Having a one-pill regimen of this kind is described as a "revolutionary step" for public health efforts. This is viewed as essential to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea worldwide.